14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
EQ vs STRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Sutro Biopharma, Inc. (STRO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas STRO carries 54.9/100 (HOLD) at $8.72 (10.0x Forward P/E, -254.7% operating margin).
Composite vs. Pillar Nuance: While STRO currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (4–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.7% operating margin) and revenue trajectory (-52.3% vs. -6.1% YoY).
Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs STRO. Trailing 12-month operating profitability (EQ 0.0% vs STRO -254.7%) and valuation multiples (EQ 1.5x vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $141.1M market capitalization and -254.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EQ vs STRO Key Questions & Quantitative Answers
As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Sutro Biopharma, Inc. (STRO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). EQ carries a Unified Composite Score of 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin), whereas STRO carries 54.9/100 (HOLD) at $8.72 (10.0x Forward P/E, -254.7% operating margin). Composite vs. Pillar Nuance: While STRO currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (4–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.7% operating margin) and revenue trajectory (-52.3% vs. -6.1% YoY). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile STRO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
STRO leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with STRO at -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin). On trailing 12-month operating scale, EQ generates $4.4M in USD-normalized revenue versus $45M for STRO. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STRO.
EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin), whereas STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus STRO (-1810.0% ROE) capital efficiency.
In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk). By comparison, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.